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Loss-of-function screening to 
identify miRNAs involved in 
senescence: tumor suppressor 
activity of miRNA-335 and its  
new target CARF
Yue Yu1,2,*, Ran Gao1,3,*, Zeenia Kaul4, Ling Li1,2, Yoshio Kato1, Zhenya Zhang2, 
Joanna Groden4, Sunil C Kaul1 & Renu Wadhwa1
Significance of microRNAs (miRs), small non-coding molecules, has been implicated in a variety of 
biological processes. Here, we recruited retroviral insertional mutagenesis to obtain induction of an 
arbitrary noncoding RNAs, and coupled it with a cell based loss-of-function (5-Aza-2′-deoxycytidine 
(5Aza-dC)-induced senescence bypass) screening system. Cells that escaped 5-Aza-dC-induced 
senescence were subjected to miR-microarray analysis with respect to the untreated control. We 
identified miR-335 as one of the upregulated miRs. In order to characterize the functional significance, 
we overexpressed miR-335 in human cancer cells and found that it caused growth suppression. We 
demonstrate that the latter accounted for inhibition of 5-Aza-dC incorporation into the cell genome, 
enabling them to escape from induction of senescence. We also report that CARF (Collaborator of ARF) 
is a new target of miR-335 that regulates its growth suppressor function by complex crosstalk with 
other proteins including p16INK4A, pRB, HDM2 and p21WAF1.
MicroRNAs (miRs) are a class of highly conserved small non-coding molecules (about 21–25 nucleotides long) 
that act as gene repressors by either causing their mRNA degradation or translational block. They are tran-
scribed as pri-miRNAs and are subsequently processed into short hairpin structured molecules by Drosha, the 
double-stranded RNA specific ribonuclease. Their involvement in diverse biological processes ranging from nor-
mal development to a variety of pathogenesis has been implicated. Hence, miR profiling has been considered to 
yield valuable outcomes, not only to understand the regulation of basic biological phenomena but also, in disease, 
diagnosis, therapy and prognosis1–3.
Cancer is a complex disease. It is regulated by multifaceted network of signaling pathways driven by loss of 
activities of tumor suppressor proteins, gain of function of oncogenes and several epigenetic mechanisms4–6. 
Many miRs, including miR-21, miR-143, miR-145, miR-182, have been found as enriched in tumors and shown 
to possess oncogenic functions7–9. On the other hand, several others including, miRNA-125b, miR-335-5p, and 
miR-34 family are downregulated in several types of cancers10–14. Recently, it was shown that the tumor suppres-
sor protein p53 regulates miRNA expression and processing, and in turn gets regulated by miRs. Restoration of 
p53-induced miRs was shown to cause suppression of tumor growth and metastasis in mouse models of cancer 
suggesting that there is a complex network of miR-p53 interactions in the regulation of p53 activities, its effectors 
and regulators15–17. Several other tumor suppressor pathways including pRB, PTEN, p16INK4A, BMI and p14ARF 
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have been shown to be either regulated by miRs or involve them for their activities to implement control on cell 
proliferation18–22. In spite of imperative emerging evidence of the role of several miRs in cancer, the molecular 
targets and mechanisms remain largely undefined. In addition, a number of miRs have also been characterized 
to possess both tumor suppressor and oncogenic functions23 warranting molecular insights to their activities in 
context of cell physiology.
Epigenetic control of cancer has been well-established6. Several epigenetic drugs (DNA methyltransferases 
and histone deacetylase inhibitors) that induce senescence in cancer cells have been in practice in conventional 
chemotherapy. However, their impact on the miRs and cancer progression remains largely unknown24. It was 
reported that miR-34 and miR-145 were silenced through DNA hypermethylation and were, hence, induced 
by 5-Aza-dC treatment25,26. In the present study, we used a retroviral vector containing GFP reporter to intro-
duce retroviral insertional mutagenesis27. Genomic integration of this vector was expected to induce tran-
scription of sequences downstream to its integration sites. Based on the fact that more than 98% of the human 
genomic DNA constitutes protein-noncoding sequences, such random integration of the vector in genome was 
expected to induce a large variety of miRNAs (referred to as arbitrary miR library). Cells expressing such random 
library of miRs were subjected to 5-Aza-dC induced senescence for 3–5 days. Whereas untransduced controls 
showed senescence phenotype, some virus-transduced cells escaped from 5-Aza-dC induced senescence (called 
loss-of-function/senescence bypass). These cells were subjected to miR-array data analysis with respect to the 
control (untransduced) cells. Out of several upregulated miRs, we characterized the function of miR-335 in the 
present study. We report that miR-335 possesses tumor suppression function, mediated, at least in part, by target-
ing CARF that in turn regulates several cell cycle monitoring proteins including p16INK4, pRb, p53 and p21WAF1.
Results and Discussion
Identification of miR-335 in 5Aza-dC induced senescence bypass. A retroviral vector constituting 
two long terminal repeat (LTR) promoters at 5′ and 3′ ends of GFP gene was generated in a way that the random 
integration of this vector in the genome would result into (i) expression of GFP; detected by green fluorescence 
and (ii) its integration site-dependent arbitrary manipulation of the host cell genome. The latter may yield loss-of-
function phenotype due to altered expression of either proteins or the noncoding microRNA regulators. We cou-
pled this system with induction of senescence in human cancer (U2OS) cells by demethylating drug, 5-Aza-dC 
(Fig. 1A). Cells treated with 5-Aza-dC showed strong induction of cellular senescence. More than 90% of control 
(virus untransduced) cells showed growth arrest and senescence associated β -gal staining in about 3–5 days. 
Small colonies appeared in virus-transduced cells at about 4–6 days. These showed green fluorescence, and hence 
were originated from transduced cells that bypassed senescence by loss of response to 5Aza-dC. The cells were 
expanded and were subjected to microRNA array with respect to the untransduced and untreated control cells 
(Fig. 1). We found several miRNAs (miR-101, miR-137, miR-145, miR-335, miR-384, miR-451, miR-545 and 
miR-558) upregulated in virus-transduced cells that showed resistance to 5-Aza-dC-induced senescence (Fig. 1 
and Supplementary Fig. 1A,B). Of note, two of these miRs (miR-145 and miR-335) have been reported to undergo 
hypermethylation-mediated silencing in a large variety of cancers25,28. Hence, their upregulation by 5-Aza-dC 
induced demethylation was justified. Furthermore, it may also be the result of retroviral insertional mutagenesis27 
(induction of transcription downstream of integration of the virus to cell genome). These data suggested that 
these miRs are involved in regulation of induction of cellular senescence, proliferation and drug response of cells. 
In the present study, we aimed to characterize such functions and targets of miR-335.
miR-335 compromises 5-Aza-dC induced senescence by inducing growth suppression. In view 
of the literature that miR-335 is silenced by hypermethylation in cancer cells25,28, we first examined if induc-
tion of senescence by 5-Aza-dC involved upregulation of miR-335 expression. Untransduced control cells were 
treated with 5-Aza-dC. Induction of senescence was tracked by examining the cell morphology and number in 
control and treated cells. At about 5–6 days post-treatment, treated cell cultures showed senescent morphology 
and growth arrest, also confirmed by senescent associated β -gal staining (Fig. 1B). Senescent cells were collected 
and subjected to miR-335 expression analysis. Contrary to our expectation, we found that miR-335 was down-
regulated in treated cells (Fig. 1B) suggesting that its upregulation, as detected by miR-array analysis, may have 
role in escape from senescence. An expression plasmid encoding primary miR-335 was transfected into U2OS 
cells. Treatment of control or miR-335-transfected cells with 5-Aza-dC and detection of senescent cells by senes-
cence associated β -gal staining revealed that prior upregulation of miR-335 indeed compromised induction of 
senescence. There was about 50% reduction in the number of SA-β -gal positive cells in miR-335 transfected cells 
(Fig. 1C). Cell viability analysis also showed that miR-335 transfected cells were less responsive to 5-Aza-dC, 
particularly at doses higher than 20 μ M (Fig. 1D) suggesting that prior upregulation of miR-335 was involved in 
the escape from 5-Aza-dC induced senescence/growth arrest. Taken together, these data suggested that miR-335 
was downregulated in cells that showed senescence upon 5-Aza-dC treatment, and that the overexpression of 
miR-335 suppressed such effect of 5-Aza-dC.
In order to clarify the mechanism of the role of miR-335 in escape from 5-Aza-dC induced senescence, we 
considered two possibilities: (i) based on the fact that incorporation of 5-Aza-dC takes place during replication 
and DNA synthesis, we hypothesized that miR-335 might cause growth arrest of cells and thus do not allow 
5-Aza-dC to be incorporated into the genome, and (ii) miR-335 may target genes that are essential for 5-Aza-dC 
induced growth arrest. We tested the first possibility by analyzing the growth and cell cycle characteristics in 
control and miR-335 transfected cells. As shown in Fig. 2, the latter were retarded in their growth (A) and showed 
lower viability in short term (B) as well as long term colony-formation assays (C). Cell cycle analysis revealed 
increase in number of cells at G0/G1, G2/M and decrease in S phase (Fig. 2D). These data suggested that miR-
335 suppressed the growth of cells that may have contributed, at least in part, to escape of cells from 5-Aza-dC 
induced senescence, as hypothesized above. miR-335 induced suppression of cell growth was also confirmed 
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by in vivo subcutaneous xenografts of control and miR-335 transfected A549 cells in nude mice (Fig. 2E). We 
found that the tumor growth of miR-335 overexpressing cells was suppressed as compared to the control cells. In 
order to investigate the relevance of miR-335 in proliferation rate of cells, we performed its expression analysis in 
normal and cancer cells. Amongst different cancer cell lines, we found ~5 fold variation in the level of miRNA. 
Nevertheless, consistent with its above described growth suppression function, miR-335 expression was ~2–4 
fold higher in normal fibroblasts as compared to a variety of cancer cells (Fig. 2F). Furthermore, in line with its 
growth suppression activity in in vitro and in vivo assays, the miR-335 overexpressing cells showed upregula-
tion of p21WAF1 (Fig. 3A,B and Supplementary Fig. 2A) and downregulation of CDK4 at protein (Fig. 3C,B and 
Supplementary Fig. 2B) and mRNA (Fig. 3D) levels. Furthermore, as expected, the growth suppression induced 
by miR-335 per se (Fig. 2A,E) was associated with substantial resistance to induction of growth arrest/senescence 
by 5-Aza-dC (Fig. 3E). As expected, increase in p21WAF1 was associated with decrease in E2F5 in miR-335 overex-
pressing cells (Fig. 3F). Simultaneous knockdown of p21WAF1 by shRNA abolished miR-335-induced decrease in 
E2F5 (Fig. 3G) resulting in recovery, at least in part, from growth suppression caused by miR-335 (Fig. 3H). These 
data suggested that p21WAF1 plays a key effector role in miR-335-induced growth suppression signaling.
Effect of miR-335 on p16INK4A and pRB, resulting in compromised 5-Aza-dC-induced senes-
cence. We next considered the second possibility that the miR-335 may target essential genes involved in 
5-Aza-dC induced growth arrest. In U2OS cells, p16INK4A (cyclin-dependent kinase inhibitor and tumor suppres-
sor) is known to undergo silencing by hyper-methylation of its promoter29. As expected, 5-Aza-dC treated cells 
showed induction of p16INK4A (Fig. 4A,B and Supplementary Fig. 2C). Of note, we found that miR-335-transfected 
cells showed downregulation of 5-Aza-dC-induced p16INK4A protein expression (Fig. 4A) suggesting that miR-
335 may target p16INK4A directly/indirectly and hence may account for escape of 5-Aza-dC-induced senescence. 
Further to confirm, we determined the expression of p16INK4A in control and miRNA-transfected cells by qPCR 
Figure 1. Identification of miR-335. Strategy for induction of miR library in human cancer cells and loss-of-
function/senescence bypass screening is described (A). The cells infected with bicistronic vector constituting 
of two promoters and GFP were treated with 5-Aza-dC. Whereas control uninfected cells showed induction of 
senescence, colonies emerged in the virus harboring cells. These colonies were expanded and pool of colonies 
was subjected to miR-array analysis with respect to the untransduced control cells. miR array analysis resulted 
in identification of miR-335 as one of the upregulated miR in cells that escaped 5-Aza-dC-induced senescence. 
Cells undergoing 5-Aza-dC-induced senescence showed down-regulation of miR-335 (B). Cells overexpressing 
miR-335 showed resistance to 5-Aza-dC-induced senescence as examined by senescence associated β -gal 
staining (C) as well as cell viability assays (D).
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using three sets of primers and, surprisingly, found increase in p16INK4A transcript not only in 5Aza-dC-treated 
controls, but also miR-335 overexpressing cells (Fig. 4C). These data suggested that the decrease in p16INK4A 
protein observed in miR-335 overexpressing cells (Fig. 4A,B) was not due to direct targeting of p16INK4A mRNA 
by miR-335.
p16INK4A is an established inhibitor of cyclin D-CDK4 complex. The latter phosphorylates retinoblastoma 
protein resulting in its dissociation from E2F family of proteins that are required for cell cycle progression. 
Accordingly, decrease in p16INK4A in miR-335 overexpressing cells was expected to result in activated cyclin 
D-CDK4 complex resulting in increased level of phosphorylated pRB in these cells. We examined the levels of 
pRB and phospho-pRB and found, contrary to the expected, decrease in phospho-pRB in miR-335 derivatives (As 
shown in Fig. 4D and Supplementary Fig. 2D). Western blotting with pRb and phospho-pRB specific antibodies 
also confirmed their downregulation in miR-335 transfected cells (Fig. 4E). qPCR analysis also revealed decrease 
in pRB transcript in miR-335 overexpressing cells (Fig. 4F) endorsing that miR-335 targets pRB. Such decrease 
in phospho-pRB was attributed to cause cell cycle retardation and escape of cells from 5-Aza-dC induced senes-
cence. Another study also showed that during differentiation of mouse embryonic stem cells, miR-335 is upreg-
ulated and causes downregulation of Oct4-pRB axis and pRB dephosphorylation19. In this report, miR-335 was 
shown to target pRB directly and specifically targeting a conserved sequence motif in its 3′ un-translated region18. 
However, it was shown to cause consequential activation of p53 tumor suppressor resulting in inhibition of cell 
proliferation and transformation. Taken together with our findings, it emerged that miR-335 is an important miR 
that controls cell proliferation by balancing the activities of pRB and p53 tumor suppressor pathways.
miR-335 targets CARF and compromises 5-Aza-dC induced senescence. In light of the informa-
tion that miR-335 targets pRB and activates p5318, we examined the level of p53 in control and miR-335 trans-
fected cells. As shown in Fig. 5, we found decrease in protein as well as mRNA level of p53 in miR-335 transfected 
cells (Fig. 5A–C and Supplementary Fig. 2E). The data suggested that miR-335 targets p53 and contributes to 
Figure 2. miR-335 overexpression caused growth suppression of cancer cells in vitro and in vivo. Growth 
curve of control and miR-335 overexpressing cells showed slower growth of the latter (A). Short and long 
term survival by viability analysis (B) and colony forming assay (C) showed about 30% and 50% reduction, 
respectively. Cell cycle analysis revealed increase in number of cells at G0/G1, G2/M and decrease in S phase 
(D). miR-335 overexpressing cells, in subcutaneous xenografts in nude mice, showed low tumor forming 
capacity as compared to the control cells. Body weight of the mice during the course of experiment showed 
no difference (E). Expression analysis of miR-335 in human normal and cancer cells showed its higher level of 
expression in normal cells (F).
www.nature.com/scientificreports/
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Figure 3. miR-335 overexpression mediated growth suppression involves upregulation of p21WAF1. miR-335 
overexpressing cells showing growth suppression possessed higher level of expression of p21WAF1 (A,B) and low 
level of expression of CDK4 (C,B). mRNA expression revealed increased level of p21WAF1 and decreased level 
of CDK4 in miR-335 overexpressing cells (D). miR-335 overexpression caused growth suppression per se, and 
resistance to 5-Aza-dC induced senescence (E). miR-335 overexpressing cells showed downregulation of E2F5 
(F) that was abolished by simultaneous knockdown of p21WAF1 using p21WAF1 specific shRNA-1 (G). Retardation 
of cell growth in miR-335 transfected cells was abrogated by shRNA mediated knockdown of p21WAF1 (H). Scale 
bars represent 20 μ m.
www.nature.com/scientificreports/
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escape of cells from 5-Aza-dC-induced senescence. However, as shown in Fig. 3B, downstream effector of p53, 
p21WAF1, showed increase in miR-335-overexpressing cells. We examined the HDM2 protein, another down-
stream effector and antagonist of p53, by immunostaining and Western blotting, and found its elevated level in 
miR-335-transfected cells (Fig. 5D,E and Supplementary Fig. 2F). These results were also supported by qPCR 
analysis (Fig. 5F) suggesting that miR-335 may target an upstream inhibitor of HDM2, leading to its increased 
levels that in turn may contribute to decreased level of p53 in miR-335 transfected cells.
CARF (Collaborator of ARF), a protein that poses two-way control on cell proliferation, has been shown to 
be an upstream regulator of p5330–32. Whereas its upregulation occurred during replicative and premature senes-
cence, its super-high level was shown to be associated with tumorigenesis and malignant transformation of cancer 
cells33. It was shown to act as a transcriptional repressor of HDM234. In view of our above findings, we examined 
CARF-p53-HDM2-p21 axis in miR-335 overexpressing cells. As shown in Fig. 6A–C and Supplementary Fig. 2G, 
these cells showed down-regulation of CARF at both protein as well as mRNA levels implying that miR-335 tar-
gets CARF, and may account for increased level of HDM2 and decreased level of p53 (Fig. 5A,D, respectively). 
Vector transfected cells did not show decrease either in CARF or in p53 (Supplementary Fig. 1C).
In order to finally resolve whether miR-335 directly targets CARF, p53 and p21WAF1, we performed reporter 
assays using 3′ UTR regions of these genes. As shown in Fig. 7A, we found that CARF, but not p53 and p21WAF1, 
was the target of miR-335. Of note, target site search for miR-335 on CARF, p53 and p21WAF1 3′ UTR gene 
sequences predicted two sites in CARF (Supplementary Fig. 1D), and none in the p53 and p21WAF1 3′ UTR. These 
data supported our above findings, and excluded p53 and p21WAF1 to be a target of miR-335. This was consist-
ent with the findings of Scarola et al.18 who reported that p53 was not the target of miR-335. Instead, it showed 
increase that was consequent to decrease in pRB in cells transiently transfected with miR-335. We also found 
increase in p53 in cells transiently transfected with miR-335 (Supplementary Fig. 1E). However, stable transfec-
tions of miR-335 caused decrease in p53 (Fig. 5A–C and Supplementary Fig. 1E) that was attributed to increased 
Figure 4. miR-335 overexpressing cells showed downregulation of p16INK4A and pRB. Immunostaining 
(A) and Western blotting (B) of control, miR-335-transfected cells treated with 5Aza-dC showed that the latter 
caused increase in expression of p16INK4A and miR-335 compromised p16INK4A increase at the protein (A,B) but  
not mRNA level (C). miR-335 transfected and 5Aza-dC treated cells showed increase in p16INK4A transcript 
that was confirmed by three sets of primers. Immunostaining (D) and Western blotting (E) for pRB in control 
and miR-335 cells revealed low level of expression of pRB and pRBphospho in the latter. miR-335 transfected cells 
showed lower level of pRB transcript (F). Scale bars represent 50 μ m in A and 20 μ m in B.
www.nature.com/scientificreports/
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level of HDM2 (Fig. 4D–F) (an established antagonist of p53) that is normally repressed by CARF34. Of note, 
CARF has been shown to act as transcriptional repressor of p21WAF1 35 and hence targeting of CARF by miR-335 
Figure 5. miR-335 overexpressing cells showed compromised expression of p53. Immunostaining  
(A) Western blotting (B) and qPCR (C) analyses for p53 showed decreased level of expression in miR-335 
overexpressing cells. The transfected cells showed higher level of expression of HDM2; immunostaining  
(D) Western blotting (E) and qPCR (F) data are shown. Scale bars represent 20 μ m.
Figure 6. miR-335 overexpressing cells showed decrease in CARF expression. Immunostaining (A) Western 
blotting (B) and qPCR (C) analysis for CARF showed decreased level of expression in miR-335 overexpressing 
cells. Scale bars represent 20 μ m.
www.nature.com/scientificreports/
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Figure 7. miR-335 targets CARF, not p53. 3′ UTR reporter assay for CARF, p53 and p21 in control and miR-
335 overexpressing cells showed that miR-335 targets CARF (A). p21WAF1 promoter reporter assay in control 
and miR-335 transfected cells showed upregulation of p21 (B). Increase in p21WAF1 occurred in p53− /− cells 
and was hence independent to that of p53 (C). Overexpression of CARF compromised miR-335 induced 
downregulation of p21WAF1 (D). siRNA-mediated knockdown of CARF strengthened the miR-335 induced 
increase in p21WAF1 (E). Schematic presentation of miR-335 targets as resolved in this study. miR-335 targets 
CARF and pRB (F). Dominant pathways are shown by solid lines. Upregulation and downregulations of 
proteins are shown by upward and downward arrows. Decrease in CARF caused (i) increase in HDM2 resulting 
in decrease in p53 and (ii) increase in p21WAF1 causing decrease in CDK4 and E2F5 (as shown in Fig. 3B,F, 
respectively) resulting in delay in cell cycle progression (shown in Figs 1 and 2).
www.nature.com/scientificreports/
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also accounted for upregulation of p21WAF1 (Fig. 3A,B) that occurred contrary to the decreased level of expression 
of p53. p21WAF1 promoter luciferase reporter assays in control and miR-335-transfected cells also showed increase 
in p21WAF1 reporter activity in the latter (Fig. 7B). Furthermore, we determined that this increase in p21WAF1 
was independent to that of p53 by using p53− /− cells (Saos-2). As shown in Fig. 7C, miR-335-transfected cells 
showed decrease in CARF and increase in p21WAF1suggesting that miR-335 targets CARF and caused increase in 
p21WAF1 independent to that of p53. In order to further validate, we reconstituted CARF in miR-335 transfected 
cells and found that an overexpression of CARF abolished the increase in p21WAF1 transfected cells (Fig. 7D). 
siRNA-mediated CARF knockdown, on the other hand, potentiated the effect of miR-335 on p21WAF1 expression 
(Fig. 7E).
CARF is an essential cell proliferation-regulatory protein that is upregulated during replicative and 
stress-induced senescence. Suppression of CARF induced aneuploidy, DNA damage and mitotic catastrophe 
resulting in apoptosis endorsing that it is an essential for cell survival31. It has been shown to bind to multiple 
proteins, p14ARF, p53 and HDM2 of ARF-p53-p21 tumor suppressor axis, and control cancer cell proliferation in 
two directions in a dose dependent way30,33,36. It was shown that while moderate level of CARF overexpression 
induced senescence, its very high level resulted in increased cell proliferation. Hence, CARF was demonstrated 
to determine the proliferative fate of cancer cells towards growth arrest, or pro-proliferative and malignant phe-
notypes by feedback and feed-forward regulatory loops of CARF-ARF-p53-HDM2-p21WAF1 axis. Molecular 
mechanism(s) of such dual regulation and how CARF is regulated in normal and cancer cells have not been fully 
understood. It was shown that CARF is involved in drug-induced senescence30. In the present study, we found 
that the cells induced to senescence (confirmed by SA-β -gal staining) in response to treatment with 5-Aza-dC 
for 5–7 days showed decrease in miR-335 (Fig. 1B). Such decrease may account for moderate increase in CARF 
and senescence through activation of p5330,31,33,36. On the other hand, prior increase in miR-335 (due to retroviral 
insertional mutagenesis) and targeting of CARF activated p21WAF−1 and resulting in growth arrest (Fig. 7B). Such 
prior induction of miR-335-induced growth arrest would inhibit the incorporation of 5-Aza-dC into the genome 
and account, at least in part, for escape of cells from 5-Aza-dC-induced senescence.
In agreement with our findings on identification of miR-335 in retrovirus-induced arbitrary manipulation 
of genome and cell based functional screening of miRs involved in escape from 5-Aza-dC induced senescence, 
Gao et al.13 and Dohi et al.28 have also reported that miR-335 expression was increased after 5-Aza-dC treatment, 
endorsing its regulation by methylation. Deletion and hypermethylation of microRNA-335 locus (7q32.2) has 
been reported in patient-derived metastatic breast and ovarian cancer cells. Its restoration inhibited migration via 
targeting extracellular matrix glycoprotein (Tenascin-C) involved in cell migration37, and was shown to induce 
premature senescence in young mesangial cells via downregulation of SOD2 and Txnrd2 with a concomitant 
increase in reactive oxygen species (ROS)38. It was also suggested as a strong inhibitor of tumor re-initiation39. 
Downregulation of miR-335 in a variety of tumors and its tumor suppressor function has recently been emerged 
in several independent studies that have also demonstrated its multiple gene targets40,41. These include RANKL 
and IGF-IR in SCLC42, BRCA1-regulatory cascade and c-Met protein in breast cancers13, OCT4 in pancreatic 
cancer43, PAX6 in glioma44, Bcl-w or BCL2L2 in the ovarian cancer45, RUNX2 in hMSCs40, ROCK1 and MAPK1 
in neuroblastoma46, Bcl-w and specificity protein 1 (SP1) in gastric cancer14,47 and ZEB2 in colorectal cancer48.
We demonstrated that CARF is a new target of miR-335 that mediates its tumor suppressor function (Fig. 7F). 
Of note, CARF silencing by shRNA has earlier been shown to cause tumor suppression in nude mice tumor for-
mation assays36, in line with tumor suppression obtained with miR-335 in the present study (Fig. 2E). Pleotropic 
effects of miR-335 demonstrated in the present study (Fig. 7F) and others (as discussed above) may be due to, at 
least in part, its control on CARF expression that has been shown to impose a dose dependent and contrasting 
effect on proliferation and malignant transformation of cancer cells33. In the present study, we demonstrated that 
targeting of CARF by miR-335 resulted in upregulation of p21WAF1 and downregulation of cyclin-CDK activity 
(Fig. 3). Furthermore, CARF has also been shown to cause upregulation of p16INK4A 31. Hence CARF-targeting 
by miR-335 also accounted for downregulation of p16INK4A protein (Fig. 4A,B) in spite of the fact that p16INK4A 
mRNA was increased in miR-335 and 5-Aza-dC treated cells (Fig. 4C). These data suggested miR-335 effects 
(such as, decrease in p16INK4A protein, increase in HDM2 and p21WAF1) and outcomes such as growth arrest are 
determined predominantly by CARF-targeting. Taken together, CARF emerged as a new strong target of miR-335 
and warrant further studies for its potential as an important noncoding tumor suppressor in cancer therapeutics.
Materials and Methods
Cell culture and drug treatment. Human osteosarcoma (U2OS and Saos-2), cervical carcinoma (HeLa), 
breast adenocarcinoma (MCF7 and MDA-MB-231), lung carcinoma (A549 and H1299) and normal human 
fibroblasts (TIG, MRC5 and WI38) were purchased from Japanese Collection of Research Bioresources (JCRB, 
Japan) and cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco BRL, Grand Island, NY, USA) sup-
plemented with 10% (v/v) fetal bovine serum (Gibco BRL), and 1% (v/v) penicillin/streptomycin in the presence 
of 5% CO2 at 37 °C as described earlier30–35. Cells were treated with 20 μ M of 5-Aza-2′ deoxycytidine (5-Aza-dC) 
(Sigma-Aldrich, St. Louis, MO, USA) for 72–96 h and subjected to the following in vitro assays.
Retrovirus infection. Exogenous expression of CARF was carried out using a retroviral carrier of 
GFP-tagged CARF that was cloned into a pCX4neo vector as previously described33 All the transfections were 
performed with FuGENE6 (Roche Applied Sciences, Basel, Switzerland), following the manufacturer’s protocol. 
Culture medium was replaced with fresh media 24 h after transfection. The viral stock was diluted 1/100, supple-
mented with 8 μ g/ml polybrene and used to infect cells for the generation of CARF overexpressing cells. Selection 
of infected clones was performed with medium containing G418 (500–900 μ g/ml) after 18–24 h to obtain stable 
GFP-CARF expressing cell lines.
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RNA interference (RNAi) and plasmid transfections. The synthesis and sequences of CARF siRNAs 
are described elsewhere30. Briefly, for annealing of siRNAs, 20 μ M of each control or target sense and antisense 
strand were incubated in annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4 and 
2 mM magnesium acetate) for 1 min at 90 °C followed by 1 h at 37 °C. siRNA duplexes was carried out using lipo-
fectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA), following the manufacturer’s protocol. Two p21 shRNA 
vectors (target sites, shRNA-1: agagttgattgaattcaac and shRNA-2: atagatttctatcatttca) were used as described ear-
lier49. The expression or shRNA vectors were transfected into cells using X-tremeGENE 9 DNA transfection 
reagent (Roche), following the manufacturer’s protocol.
Induction of arbitrary miR library and screening for miRNAs involved in escape from 5Aza-dC 
induced senescence. To construct a retroviral vector pMXGbu, a short linker with 5′ - gaattAGCGGAG-
GACAGTACTCCGATCGGAGGACAGTACTCCGTtcgac -3′ was inserted between EcoRI and SalI sites of pMX-
CRGb50 by removing CMV-RFP cassette. Upon transduction, the upstream LTR of the vector drives GFP-Bsd 
fusion gene and the downstream LTR initiates random transcription resulting into retroviral insertional mutagen-
esis27 and thus arbitrary alteration of gene expression. The transduced cells were selected in blasticidin (10 μ g/ml) 
supplemented medium and were then subjected to 5Aza-dC (20 μ M) for 3–5 days. The cells were subsequently 
harvested to prepare total RNA (RNeasy Plus Mini Kit (QIAGEN).
miRNA array. Control (untransduced and untreated) and virus transduced and 5-Aza-dC (20 μ M) treated 
cells (pooled colonies) that escaped senescence were harvested. For miRNA microarray, small RNAs (less than 
200 nt including precursor and mature miRNAs) were extracted using mirVana miRNA isolation kit (Ambion, 
Austin, TX, USA) following the manufacturer’s protocol. Purified RNA was labeled with Cy3 or Cy5 using the 
mirVana miRNA labeling kit (Ambion). Labeled RNA was hybridized with oligonucleotides against human miRs 
(~500) arrayed on slides (Hokkaido-System Science, Japan), and detected by a scanner (Agilent Technologies, 
Santa Clara, CA, USA). miRs that showed more than 2 fold change in expression were considered for further 
analysis.
Cloning of miR-335, expression plasmid. pCXGb-miR-335: a primary miR-335 region was amplified 
from human genomic DNA by PCR using the following primers: 5′ -AACTCGAGTTCAGCCTTCATTG 
TTTAATCTTTACAACAGC-3′ and 5′ - AAGATATCTGTATGGACATGAAGCTTTTACTTCAACATTAG-3′ . 
The PCR product was digested with SalI and EcoRV and introduced into pCXGb as described earlier51.
Senescence-associated β-galactosidase assay (SA-β-gal). SA-β -gal detection kit (Cell Signaling 
Technology, Danvers, MA, USA) was used following manufacturer’s instructions. Cells showing blue staining 
were considered positive and counted under the microscope quantitation from three independent experiments 
was performed.
Flow cytometry. Control and transfected cells were harvested by trypsin (0.25%). Cell pellets were washed 
with cold PBS and then added drop-wise to pre-chilled 70% ethanol. The fixed cells were centrifuged at 800 Xg  
for 5 min at 4 °C, washed with cold PBS twice and then re-suspended in 0.25 ml PBS. The cells suspensions 
were treated with RNase A at 37 °C for 1 h followed by brief centrifugation to discard supernatant. Cells were 
re-suspended in 200 μ l of Cell Cycle Guava reagent (Millipore, Billerica, MA, USA), incubated for 30 min in dark, 
and analyzed by EasyCyte Guava cytometer (Millipore). The data were further analyzed using FlowJo software.
Cell viability, proliferation and colony forming assay. Equal number of control and transfected cells 
were plated in 96-well plates. After 48 h of incubation at 37 °C, 100 μ l of MTT (Sigma-Aldrich) in PBS (5 mg/ml) 
was added to each well. After 4 h of incubation at 37 °C, the supernatant was discarded and the precipitate was 
dissolved with 100 ml of dimethyl sulfoxide (DMSO). Plates were then read on a microplate reader (infinite M200 
PRO, TECAN) at 570 nm.
For cell proliferation assay, control and transfected cells were plated onto 12-well plates. Cells were harvested 
and counted in triplicates at the indicated time point using TC20TMAutomated Cell Counter (Bio-Rad, Hercules, 
CA, USA), with trypan blue exclusion to identify viable cells. Growth curves were generated for each cell line 
from three independent experiments.
For long-term cell viability and proliferation, colony-forming assay was performed. 500 cells were plated in a 
6-well plate and left to form colonies for the next 10–15 days with a regular change of medium on every third day. 
Colonies were fixed with pre-chilled methanol/acetone (1/1, v/v) 10 min on ice, stained with 0.1% crystal violet 
solution, photographed and counted.
Cloning of pMIR-CARF-3′UTR plasmid. CARF-3′ untranslated region (UTR) was amplified by PCR 
(initial 10 min denaturation step at 98 °C followed by 30 cycles of 98 °C for 30 s, 55 °C for 30 s and 72 °C for 30 s, 
with a final annealing step at 72 °C for 10 min) using human genomic DNA with primers: 5′ -GTTTAAACGTTTAA 
ACTGTGTCCAAAATATCACTGC-3′ and 5′ -ACTAGTACTAGTCTAACAGACACGTTCAAC-3′ . The PCR 
product was digested with Pme1 and Spe1, and then introduced into pMIR-REPORTTM Luciferase plasmid 
(Applied Biosystems, Forster, CA, USA) between these two sites.
Luciferase reporter assay. The pGL4-p53-3′ UTR and pGL4-p21-3′ UTR were generously provided by Dr. 
Chae-Ok Yun (Hanyang University, Seoul, South Korea). U2OS control and miR-335 transfected cells were trans-
fected with 1 μ g of luciferase constructs (pGL4-p53-3′ UTR, pGL4-p21-3′ UTR or pMIR-CARF-3′ UTR), 100 ng of 
control vector oligonucleotide (pRL-TK or pMIR-REPORTTM β -gal control plasmid) using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA, USA). After 24–48 h, luciferase activity was measured using a dual luciferase reporter 
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assay system and β -gal enzyme system (Promega, Madison, WI, USA) following the manufacturer’s protocol. 
Experiments were carried out in triplicate and repeated at least three times.
RNA extraction and real-time qRT-PCR. Total RNA was isolated from cells using the RNeasy mini kit 
(Qiagen, Standford Valencia, CA, USA). The concentration and purity of RNA were determined by ultraviolet 
spectrophotometry (A260/A280 > 1.9) using NanoDrop ND-1000 (Nanodrop Technologies, Wilmington, DE, 
USA).
Equal amount of RNA were used for reverse transcription following the protocol of QuantiTect Reverse 
Transcription Kit (Qiagen). The real-time qRT-PCR (50 °C for 2 min; 95 °C for 10 min, 40 cycles of 95 °C for 15 s, 
60 °C for 1 min; and 72 °C for 30 s) was performed using SYBR® Select Master Mix (Applied Biosystems in tripli-
cate on the Eco™ real time system (Illumina, San Diego, CA USA). The real-time qRT-PCR results were analyzed 
and expressed as relative expression of threshold cycle value that was then converted to x-fold changes (2−∆∆ Ct) 
following manufacturer’s instructions and primer sets (listed in Table 1).
For miR-335 expression analysis, the corresponding miR-335 (Assay ID: 000546) and RNU6B (Assay ID: 
001093) primers and TaqMan® MicroRNA assay was performed following the manufacturer’s instructions 
(Applied Biosystems). RNU6B served as an endogenous control for normalization. Real-time qRT-PCR was con-
ducted at 95 °C for 10 min, 40 cycles of 95 °C for 15 s and 65 °C for 1 min. Stem loop sequence of miR-335 and 
RNU6B are described in Table 2.
Western blotting. Cells were harvested using RIPA buffer (Thermo Scientific, Waltham, MA, USA) sup-
plemented with a protease inhibitor cocktail (Roche). The protein concentrations were determined by using the 
Pierce BCA Protein Assay Kit (Thermo Scientific). Western blotting was performed as described earlier35 using 
following antibodies: Anti-p16 (C-20), anti-p21 (C-19), anti-p53 (DO-1), anti-MDM2 (HDM2-232), anti-Cdk4 
(C-22), anti-E2F (MH5), anti-GFP (B-2) (Santa Cruz, CA, USA), anti-Phospho-Rb (Ser780), anti-Rb (4H1) (Cell 
Signaling, Danvers, MA, USA) and anti-CARF (FLA-10)52. Anti-β -actin antibody (AC-15) (Abcam, Cambridge, 
MA, USA) was used as an internal loading control. All the experiments were performed in triplicate at least three 
times.
Immunostaining. Cells were cultured on a glass coverslip placed in a 12-well culture dish. For immunos-
taining, cells wee washed (cold PBS), fixed (pre-chilled methanol/acetone (1:1) mixture for 10 min), permea-
bilized (0.5% Triton X-100 in PBS for 10 min), blocked (0.2% BSA/PBS for 1 h) and were then incubated with 
specific antibody (as described above) for overnight at 4 °C. They were incubated with Alexa-594-conjugated goat 
anti-mouse or anti-rabbit (Molecular Probes, Invitrogen) secondary antibodies after washings (thrice) with 0.2% 
miR-335 UGUUUUGAGCGGGGGUCAAGAGCAAUAACGAAAAAUGUUUGUCAUAAACCGUUUUUCAUUAUUGCUCCUG ACCUCCUCUCAUUUGCUAUAUUCA
RNU6B GCAAGGATGACACGCAAATTCGTGAAGCGTTCCATATTTTT
Table 2.  Stem loop sequence.
Gene (human) Sequence (5′ -3′ )
p21WAF1 forward GAGGCCGGGATGAGTTGGGAGGAG
p21WAF1 reverse CAGCCGGCGTTTGGAGTGGTAGAA
CDK4 forward TCGAAAGCCTCTCTTCTGTG
CDK4 reverse TACATCTCGAGGCCAGTCAT
p16INK4a (1) forward CCCAACGCACCGAATAGTTA
p16INK4a (1) reverse ACCAGCGTGTCCAGGAAG
p16INK4a (2) forward GAAGGTCCCTCAGACATCCCC
p16INK4a (2) reverse CCCTGTAGGACCTTCGGTGAC
p16INK4a (3) forward CCCCTTGCCTGGAAAGATAC
p16INK4a (3) reverse AGCCCCTCCTCTTTCTTCCT
Rb forward GGAAGCAACCCTCCTAAACC
Rb reverse TTTCTGCTTTTGCATTCGTG
p53 forward TAACAGTTCCTGCATGGGCGGC
p53 reverse AGGACAGGCACAAACACGCACC
HDM2 forward TAGTATTTCCCTTTCCTTTGATGA
HDM2 reverse CACTCTCCCCTGCCTGATAC
CARF forward TCAAAGTGACAGATGCTCCA
CARF reverse CGTTGAACTGTTTTCCTGCT
18s forward CAGGGTTCGATTCCGTAGAG
18s reverse CCTCCAGTGGATCCTCGTTA
Table 1.  qRT-PCR primer set sequences.
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Triton X-100 in PBS. Counterstaining was performed with Hoechst 33342 (Sigma) for 10 min in dark following by 
extensive washings with 0.2% Triton X-100 in PBS and observations under a Carl Zeiss microscope (Axiovert 200 
M, Tokyo, Japan)35. At least 200 cells (from 2–5 random fields in view) were evaluated for quantitation of immu-
nofluorescence signals. Images were quantified by ImageJ software (National Institute of Health, Bethesda, MD).
In vivo tumor formation assay. Balb/c nude mice (4 weeks old, female) were provided by the Institute of 
Laboratory Animal Science of Peking Union Medical College. Cells (A549 and A549-miR335 transfected cells.) 
were injected into the nude mice subcutaneously (5 × 106 suspended in 0.2 ml of growth medium). Tumor for-
mation and mice health (body weight) was monitored every alternate day. The experiment was repeated twice, 
using 4 mice in each group. Volume of the subcutaneous tumors was calculated as V = L × W2/2, where L was 
length and W was the width of the tumor, respectively. Protocols for animal experiments were approved by the 
Animal Care and Use Committee, Institute of Laboratory Animal Science of Peking Union Medical College 
(ILAS-PG-2014-018).
Statistical analysis. All experiments were carried out more than three times, and data were expressed as 
mean ± standard deviation (SD). Data were represented with respect to the control that were set either at 100 or 
1 as shown. Two-tailed Student’s t-test or nonparametric ManneWhitney U-test, whichever was applicable, was 
used to determine the degree of significance between the control and experimental sample. Statistical signifi-
cance was defined as significant (*p-value ≤ 0.05), very significant (**p-value ≤ 0.01) and very very significant 
(***p-value ≤ 0.01).
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